What Are Radiopharmaceuticals and How Are They Used in MBC?
Radiopharmaceuticals are drugs attached to radioactive molecules. Click here to learn about their safety and how they are being studied in clinical trials to help diagnose and treat MBC.
Radiopharmaceuticals are drugs attached to radioactive molecules. Click here to learn about their safety and how they are being studied in clinical trials to help diagnose and treat MBC.
Local therapy is important for managing symptoms related to MBC with liver mets. Learn how Yttrium-90 internal radiation therapy (Y-90) may increase survival.
Learn about the side effects of brain tumor radiation, why you might experience a specific side effect, and how medications, diet, and lifestyle changes may help.
Do you need surgery or radiation to the breast after an MBC diagnosis? See the current research on this important question.
When breast cancer spreads, one of the first sites it often goes to is bone. The articles below discuss diagnosis and treatment of bone metastases.
Bone metastases, like other types of metastases, are often treated with systemic treatments, such as chemotherapy, hormone therapy (if your cancer is estrogen or progesterone receptor-positive), targeted therapies, and bone-strengthening drugs. Radiation may also be used to treat certain metastatic sites.
Studies suggest that between 15 and 30 percent of women and men with metastatic breast cancer will develop brain metastases. This number has been increasing as MBC patients live longer on treatments that control cancer growth in other areas of the body.
Clinical trials are currently looking at the best way to treat brain metastases. In September, the FDA approved neratinib (Nerlynx®) as a treatment for HER2-positive metastatic breast cancer. Its previous approval was for extended adjuvant treatment for patients with early-stage HER2+ breast cancer who have already received trastuzumab (Herceptin®).
With the links below, you can learn more about developments in treating breast cancer brain metastases and the new FDA approval. You can also find links to all the clinical trials listed on BCT for breast cancer brain metastases, including the first trial to use CAR T cell therapy to treat HER2+ brain metastases.